{"organizations": [], "uuid": "9fc3e76f6fc43b1c15617e77a0de22f62d70afb2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-acceleron-receives-fda-fast-track/brief-acceleron-receives-fda-fast-track-designation-for-ace-083-in-facioscapulohumeral-muscular-dystrophy-idUSASC09YIN", "country": "US", "domain_rank": 408, "title": "BRIEF-Acceleron Receives FDA Fast Track Designation For Ace-083 In Facioscapulohumeral Muscular Dystrophy", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-01T14:49:00.000+03:00", "replies_count": 0, "uuid": "9fc3e76f6fc43b1c15617e77a0de22f62d70afb2"}, "author": "", "url": "https://www.reuters.com/article/brief-acceleron-receives-fda-fast-track/brief-acceleron-receives-fda-fast-track-designation-for-ace-083-in-facioscapulohumeral-muscular-dystrophy-idUSASC09YIN", "ord_in_thread": 0, "title": "BRIEF-Acceleron Receives FDA Fast Track Designation For Ace-083 In Facioscapulohumeral Muscular Dystrophy", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "acceleron pharma inc", "sentiment": "none"}, {"name": "facioscapulohumeral muscular dystrophy reuters staff", "sentiment": "none"}, {"name": "acceleron", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 1, 2018 / 11:51 AM / Updated 9 minutes ago BRIEF-Acceleron Receives FDA Fast Track Designation For Ace-083 In Facioscapulohumeral Muscular Dystrophy Reuters Staff 1 Min Read\nMay 1 (Reuters) - Acceleron Pharma Inc:\n* ACCELERON RECEIVES FDA FAST TRACK DESIGNATION FOR ACE-083 IN FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-05-01T14:49:00.000+03:00", "crawled": "2018-05-01T15:10:32.037+03:00", "highlightTitle": ""}